Husnu Umit Kaniskan

Assistant Professor

Icahn School of Medicine at Mount Sinai

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Husnu Umit Kaniskan is an Assistant Professor at the Icahn School of Medicine at Mount Sinai, USA. His research primarily focuses on the development of novel therapeutic strategies, including brain-penetrant HCN channel inhibitors and proteolysis-targeting chimeras for various malignancies. Recent publications highlight his work on oncogenic activities in synovial sarcoma, modulation of BCR signaling in mantle cell lymphoma, and the structural diversity of psychedelic drug actions.

Articles (15)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Husnu Umit Kaniskan

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

SOX11 Modulates BCR Signaling Through the PAX5/CD19 Axis for Therapeutic Targeting in BTK Resistant Mantle Cell Lymphoma

Design and validation of novel brain-penetrant HCN channel inhibitors to ameliorate social stress-induced susceptible phenotype

Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma

The structural diversity of psychedelic drug actions revealed

De Novo Design of κ-Opioid Receptor Antagonists Using a Generative Deep-Learning Framework

Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53

Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins

Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer

Chemically induced degradation of epigenetic targets

Methylated Nucleotide-Based Proteolysis-Targeting Chimera Enables Targeted Degradation of Methyl-CpG-Binding Protein 2

Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos

TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors

Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2

Advancing targeted protein degradation for cancer therapy

Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras

Collaborators (5)

G Greg Wang

Davide Provasi

Heng-Huan Lee

Marta Filizola

Zhen Wang

Make your next move.